These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 12897580

  • 1. Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications: a two-center randomized prospective trial.
    Gandolfi SA, Rossetti L, Cimino L, Mora P, Tardini M, Orzalesi N.
    J Glaucoma; 2003 Aug; 12(4):347-53. PubMed ID: 12897580
    [Abstract] [Full Text] [Related]

  • 2. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
    Simmons ST, Samuelson TW.
    Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
    [Abstract] [Full Text] [Related]

  • 3. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG.
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece.
    Petounis A, Mylopoulos N, Kandarakis A, Andreanos D, Dimitrakoulias N.
    J Glaucoma; 2001 Aug; 10(4):316-24. PubMed ID: 11558817
    [Abstract] [Full Text] [Related]

  • 5. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K, Shirato S.
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [Abstract] [Full Text] [Related]

  • 6. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma.
    Polo V, Larrosa JM, Gomez ML, Pablo L, Honrubia FM.
    Acta Ophthalmol Scand; 2001 Feb; 79(1):6-9. PubMed ID: 11167277
    [Abstract] [Full Text] [Related]

  • 7. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST, Earl ML, Alphagan/Xalatan Study Group.
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [Abstract] [Full Text] [Related]

  • 8. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C, Oksüz H.
    Ophthalmic Res; 2007 Feb; 39(1):24-31. PubMed ID: 17164574
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
    Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA, COSOPT versus XALATAN Study Groups.
    Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
    [Abstract] [Full Text] [Related]

  • 12. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M.
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J.
    Eur J Ophthalmol; 2000 May; 10(3):198-204. PubMed ID: 11071026
    [Abstract] [Full Text] [Related]

  • 14. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE, Lai J.
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [Abstract] [Full Text] [Related]

  • 15. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM, McGavin JK, Culy CR, Ibbotson T.
    Drugs Aging; 2003 Sep; 20(8):597-630. PubMed ID: 12795627
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma.
    Ozdemir M, Ozdemir G.
    Jpn J Ophthalmol; 2003 Sep; 47(1):72-6. PubMed ID: 12586182
    [Abstract] [Full Text] [Related]

  • 17. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M, Reis A, Sano ME, Susanna R.
    J Glaucoma; 2010 Sep; 19(5):331-5. PubMed ID: 19730119
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC, Sharpe ED, Day DG, Kolker AE, Konstas AG, Lee WH, Rieser JC, Chopra H, Holmes KT.
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.